Table 2.
Comparison of Basic Characteristics of Participants by Vaccine Type.
| Vaccine Type | FD N (%) |
SD N (%) |
Age (Mean-SD) | Gender N (%) |
COVID-19 Positive History N (%) |
Comorbidity N (%) |
|---|---|---|---|---|---|---|
| Sputnik V | 683 (45.53) |
667 (45.49%) |
35.56 (8.02) | M: 287 (42) F: 396 (58) |
350 (51.2) | DM: 8 (1.2) HTN: 9 (1.3) DM+HTN: 2 (0.3) TD: 16 (2.3) Other: 27 (3.9) |
| Sinopharm | 325 (21.66) |
314 (21.41) |
37.57 (8.98) | M: 152 (46.8) F: 173 (53.2) |
210 (64.6) | DM: 4 (1.2) HTN: 8 (2.5) DM+HTN: 3 (0.9) TD: 4 (1.2) Other: 27 (8.3) |
| Oxford AstraZeneca | 274 (16.46) |
270 (18.41) |
36.59 (7.75) | M: 138 (50.4) F: 136 (49.6) |
171 (62.4) | DM: 3 (1.1) HTN: 5 (1.8) DM+HTN: 0 (0) TD: 1 (0.4) Other: 7 (2.55) |
| Covaxin | 140 (0.09) |
137 (0.09) |
37.08 (6.29) | M: 40 (28.6) F: 100 (71.4) |
81 (57.9) | DM: 0 (0) HTN: 1 (0.7) DM+HTN: 0 (0) TD: 2 (1.4) Other: 7 (5) |
| COVIran Barekat | 78 (0.05) |
78 (0.05) |
36.50 (6.17) | M: 34 (43.6) F: 44 (56.4) |
59 (75.6) | DM: 0 (0) HTN: 2 (2.6) DM+HTN: 1 (1.3) TD: 0(0) Other: 1 (1.3) |
| Total | 1500 | 1466 | ||||
| Test p-Value | Kruskal–Wallis p-Value = 0.003 | χ2p-Value = 0.001 | χ2p-Value < 0.001 | χ2p-Value = 0.859 | ||
N: number of participants; FD: first dose; SD: second dose; M: male; F: female; DM: diabetes mellitus; HTN: hypertension; TD: thyroid disorders.